The Dementia Discovery Fund is a £250m specialist venture capital fund investing in and creating biotech enterprises focused on transformational therapeutics for dementias, managed by SV Health Investors.
Portfolio
2
companies
Cumulus Neuroscience
Digital biomarker platform provider for neuroscience clinical trials and patient monitoring.
NRG Therapeutics
NRG Therapeutics develops mitochondrial-targeted treatments for neurodegenerative conditions.
Ruth McKernan
venture partner and co-founder
Ruth brings neuroscientific and entrepreneurial experience, having co-founded the Dementia Discovery Fund and held venture partner roles at SV Health Investors. She currently serves as executive chair at Draig Therapeutics.
LinkedInThe financing round was led by SV Health Investors and will fund initial human trials for the company lead candidate in ALS and Parkinson's.
"Developing new drugs to treat neurological diseases is very challenging, but is receiving increased interest given the high unmet medical need and growing prevalence in ageing populations."
The financing round was led by the Dementia Discovery Fund with backing from LifeArc and the UK Future Fund.
"We are delighted that DDF and LifeArc share our mission, addressing the clear need for more effective tools to provide the critical clinical trial data and analysis needed to improve the successful delivery of new CNS therapies to patients. This funding will allow us to build on the ground-breaking advances we have made in remote, frequent monitoring of brain activity and cognitive function in the home, in partnership with leading developers of digital biomarkers. We believe our integrated next generation platform can improve the execution of clinical trials by yielding significant time and cost savings, adding meaningful value to the next generation of CNS therapies."
